Relationship between 18F-FDG PET/CT Lugano lymphoma response evaluation criteria and prognosis at the end of chemotherapy for diffuse large B-cell lymphoma

Fengchun WU; Zhaoqi ZHANG; Xinming ZHAO; Lijiao ZENG; Kun WANG.
Chinese Journal of Nuclear Medicine and Molecular Imaging ; (6): 209-215, 2022.
Artículo en Zh | WPRIM | ID: wpr-932916

Documentos relacionados

  1. Prognostic Impact of Pretreatment 2-[<sup>18</sup>F]-FDG PET/CT Parameters in Primary Gastric DLBCL.
  2. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
  3. The prognostic value of splenic abnormalities in pretreatment <sup>18</sup>F-FDG PET/CT in patients with complete response diffuse large B-cell lymphoma.
  4. Predictive value of Dmax and %&#916;SUVmax of <sup>18</sup>F-FDG PET/CT for the prognosis of patients with diffuse large B-cell lymphoma.
  5. Appropriate timing to perform an interim <sup>18</sup>F-FDG PET/CT in patients with nasal-type extranodal natural killer/T cell lymphoma.
  6. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
  7. [Prognostic Value of <sup>18</sup>F-FDG PET/CT Metabolic Parameters in Patients with Diffuse Large B-Cell Lymphoma].
  8. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on <sup>18</sup>F-FDG and <sup>18</sup>F-OC for Neuroendocrine Neoplasms.
  9. Role of body composition and metabolic parameters extracted from baseline <sup>18</sup>F-FDG PET/CT in patients with diffuse large B-cell lymphoma.
  10. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].